After finishing at $10.68 in the prior trading day, Roivant Sciences Ltd (NASDAQ: ROIV) closed at $10.44, down -2.25%. In other words, the price has decreased by -$0.24 from its previous closing price. On the day, 5755562 shares were traded. ROIV stock price reached its highest trading level at $10.78 during the session, while it also had its lowest trading level at $10.40.
Ratios:
Our goal is to gain a better understanding of ROIV by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 27.77 and its Current Ratio is at 27.79. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on February 15, 2024, initiated with a Outperform rating and assigned the stock a target price of $17.
On January 05, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $20.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $14.Deutsche Bank initiated its Buy rating on December 12, 2023, with a $14 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 09 ’24 when Venker Eric sold 96,950 shares for $10.92 per share. The transaction valued at 1,058,694 led to the insider holds 532,207 shares of the business.
Ramaswamy Vivek sold 3,000,000 shares of ROIV for $33,150,000 on Jan 02 ’24. The 10% Owner now owns 51,929,426 shares after completing the transaction at $11.05 per share. On Oct 05 ’23, another insider, Venker Eric, who serves as the Chief Operating Officer of the company, sold 153,027 shares for $10.11 each. As a result, the insider received 1,547,103 and left with 595,397 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ROIV now has a Market Capitalization of 8.61B and an Enterprise Value of 2.45B. As of this moment, Roivant’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.00. For the stock, the TTM Price-to-Sale (P/S) ratio is 68.27 while its Price-to-Book (P/B) ratio in mrq is 1.38. Its current Enterprise Value per Revenue stands at 19.88 whereas that against EBITDA is 0.57.
Stock Price History:
Over the past 52 weeks, ROIV has reached a high of $13.24, while it has fallen to a 52-week low of $6.59. The 50-Day Moving Average of the stock is 10.95, while the 200-Day Moving Average is calculated to be 10.50.
Shares Statistics:
The stock has traded on average 5.46M shares per day over the past 3-months and 5.19M shares per day over the last 10 days, according to various share statistics. A total of 760.14M shares are outstanding, with a floating share count of 482.18M. Insiders hold about 40.16% of the company’s shares, while institutions hold 50.51% stake in the company. Shares short for ROIV as of Feb 15, 2024 were 28.77M with a Short Ratio of 5.26, compared to 31.99M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.57% and a Short% of Float of 6.69%.
Earnings Estimates
Its stock is currently analyzed by 7 different market analysts. On average, analysts expect EPS of -$0.3 for the current quarter, with a high estimate of -$0.24 and a low estimate of -$0.37, while EPS last year was -$0.2. The consensus estimate for the next quarter is -$0.45, with high estimates of -$0.28 and low estimates of -$1.03.
Analysts are recommending an EPS of between $5.46 and -$0.93 for the fiscal current year, implying an average EPS of $4.55. EPS for the following year is -$1.15, with 8 analysts recommending between -$0.58 and -$1.47.
Revenue Estimates
10 analysts predict $33.15M in revenue for the current quarter. It ranges from a high estimate of $41M to a low estimate of $27.5M. As of the current estimate, Roivant Sciences Ltd’s year-ago sales were $27.38M, an estimated increase of 21.10% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $48.84M, an increase of 94.80% over than the figure of $21.10% in the same quarter last year. There is a high estimate of $142.7M for the next quarter, whereas the lowest estimate is $30M.
A total of 12 analysts have provided revenue estimates for ROIV’s current fiscal year. The highest revenue estimate was $291M, while the lowest revenue estimate was $123.3M, resulting in an average revenue estimate of $143.74M. In the same quarter a year ago, actual revenue was $61.28M, up 134.60% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $174.18M in the next fiscal year. The high estimate is $242.19M and the low estimate is $134M. The average revenue growth estimate for next year is up 21.20% from the average revenue estimate for this year.
